1. Inicio
  2. Publicaciones
  3. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ferris, RL
  • Haddad, R
  • Even, C
  • Tahara, M
  • Dvorkin, M
  • Ciuleanu, TE
  • Clement, PM
  • Mesia, R
  • Kutukova, S
  • Zholudeva, L
  • Daste, A
  • Keam, B
  • Vynnychenko, I
  • Lafond, C
  • Shetty, J
  • Mann, H
  • Fan, J
  • Wildsmith, S
  • Morsli, N
  • Fayette, J
  • Licitra, L

Abstract

Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has shown evidence of additive activity in several tumor types. This phase III study evaluated the efficacy of durvalumab (an anti-PD-L1 monoclonal antibody) or durvalumab plus tremelimumab (an anti-CTLA-4 monoclonal antibody) versus standard of care (SoC) in R/M HNSCC patients.

Datos de la publicación

ISSN/ISSNe:
0923-7534, 1569-8041

ANNALS OF ONCOLOGY  ELSEVIER

Tipo:
Article
Páginas:
942-950
PubMed:
32294530
Factor de Impacto:
7,954 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 310

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • durvalumab, head and neck squamous cell carcinoma, immunotherapy, metastatic, randomized clinical trial, tremelimumab

Campos de Estudio

Cita

Compartir